Active substance | Valganciclovir |
US Brand | Valcyte |
IN Brand | Valgan |
Manufacturing by | Cipla |
Strength | blister 4 tabs |
Form release | 450mg |
Estimated shipping time | 7 – 18 days (Depending from the Country) |
Availability, Prices & Order | through request form |
is an antiviral medication used to treat cytomegalovirus (CMV) infection in those with HIV/AIDS or following organ transplant. It is often used long term as it only suppresses rather than cures the infection. Valganciclovir is taken by mouth.
Common side effects include abdominal pain, headaches, trouble sleeping, nausea, fever, and low blood cell counts. Other side effects may include infertility and kidney problems. When used during pregnancy, it causes birth defects in some animals. Valganciclovir is the L-valyl ester of ganciclovir and works when broken down into ganciclovir by the intestine and liver.
Usual Adult Dose for CMV Retinitis
Induction dose: 900 mg orally twice a day for 21 days
Maintenance dose: 900 mg orally once a day
Comments:
-The tablet formulation should be used, not the oral solution.
-The maintenance dose should be used after the induction dose or in patients with inactive CMV retinitis.
Use: For the treatment of CMV retinitis in patients with AIDS
Usual Adult Dose for CMV Prophylaxis
900 mg orally once a day
Duration of therapy:
-Heart or kidney-pancreas transplant patients: Until 100 days posttransplantation.
-Kidney transplant patients: Until 200 days posttransplantation.
Comments:
-The tablet formulation should be used, not the oral solution.
-Therapy should be started within 10 days of transplantation.
Use: For the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant recipients at high risk (donor CMV seropositive/recipient CMV seronegative)
Valganciclovir is commonly associated with vomiting, abdominal pain, diarrhea, and headache.